BIOTECH MEDTECH PHARMA - visit site

comparisonsneezeΒιοτεχνολογία

1 Δεκ 2012 (πριν από 4 χρόνια και 8 μήνες)

228 εμφανίσεις

2
|
Introducing Biopeople
4
|
Unique partnerships
6
|
Science dating
7
|
Education and training initiatives
10
|
Biopeople – the Danish Pharma Industry
12
|
Top clinical and translational R&D
13
|
Bioethics forum
14
|
Research projects
14
|
Corporate membership
15
|
Bioinformatics and systems biology
16
|
Biopeople - the Danish MedTech Industry
18
|
Danish MedTech
22
|
Biopeople - the Danish Biotech Industry
24
|
Regional organisations and networks
25
|
Biotech partnering missions
26
|
Online databases
27
|
Preclinical and translational R&D
Biotech Medtech PharMa
InTRODUCIng BIOPEOPlE
Interview with Chairman Knut Conradsen, Vice Rector at the Technical University of Denmark
How great is the need for the Biopeople Life science innovation network?
Biopeople is a merger and expansion of two earlier networks: one for the biomedical, health
professional, and pharmaceutical fields, and the other for systems biology and bioinformatics.
Now the Biopeople innovation network covers all of pharma, biotech and MedTech.
The concentration of all these areas within Biopeople is an improvement because it operates
across disciplines, because it increases patterns of cooperation in public-private partnering,
and because it enables cooperation across the entire nation.
All experience shows that these features will lead to the inclusion of more and more relevant
competences. Biopeople creates an advanced form of network groupings, where the synergies
are both created and exploited.
What new opportunities do you see arising from the Biopeople innovation network?
Many, but it is clear that with its national coverage Biopeople will have a much better knowledge
of the region-specific conditions in the other regions in Denmark.
There is of course no past performance applicable in this situation, but it seems logical that
the representation of several disciplines and the resulting wider competencies will result in a
strengthening of innovation by Biopeople, provided it is combined with greater transparency
about knowledge sharing. Biopeople’s work includes interdisciplinary research and develop-
ment, matchmaking, knowledge sharing, facilitation of collaborative projects, and education
and training. Its innovation areas include biomedical research and development, Life science
innovation, medical device research and development, and biotechnology. Facilitation of
public-private research and development cooperation as well as building bridges between
disciplines are both important to encourage innovation and to ensure that Denmark will continue
to maintain its world position as a knowledge society with a knowledge-based economy. The
Danish Agency for Science, Technology and Innovation has implemented a merger of former
regional and national initiatives through its new innovation networks, thereby ensuring a
stronger and better coordinated set of initiatives.
Traditionally, development and innovation occurred via the interplay between industry, universi-
ties and hospitals with each region in Denmark. The new national network will boost innovation
and matchmaking among these regions and coordinate it across them, and so provide better
opportunities for the implementation of clinical trials in the best settings – in those hospitals
with departments that have specialized in the relevant clinical areas.
2
What is your assessment of the development potential of Life science
innovation in Denmark?
We are strong today, but our potential is underutilized. And there is no future
for us in low-cost products. To maintain and develop our leading position, we
must use our knowledge very effectively and at a high level. The relative share
of the national research budgets used for technology is only half the amount
allocated in those countries we usually compare ourselves with, both OECD
countries and others. It is vital that we exploit our existing possibilities to our
utmost. For example, our research environment and research tradition has
many strong sides compared to what we see in Korea and China, which have
until now mostly focused on the business results of research. But the Danish
research policy is too weakly focused upon the relevance of given research
activities. We must realize that development and innovation in healthcare will
be driven by major new interdisciplinary knowledge, which both implies and
leads to new technologies. We must get down and measure the human genome
in single cells. Technologies in science, health sciences, and pharmacy must
be part of an interaction where the one draws upon the resources of the other
and creates “multi-synergies”. To this end, networks between disciplines are
quite effective and absolutely necessary.
The forums we can set up to combine innovation will provide us with both good
models and good data, and increase our ability to develop new prevention and
treatment approaches as well as to design new medicinal and medical device
products. We must not put all our efforts into one system, but seek a broad
understanding. Biopeople should not be a network for people who want to solve
a specific puzzle, but a network for all of those who have skills and interests
in producing health treatments and in finding new treatment directions and
treatment methods.
About The Technical University of Denmark
DTU is a self-governing university offering education, research, governmental
service, and innovation.
The university’s main tasks are performed by 18 different departments and a
national laboratory located on its Lyngby campus north of Copenhagen and
in several other locations throughout Copenhagen, on Zealand and in Jutland.
The university owns several costly experimental facilities.
With extensive research in traditional engineering disciplines as well as in
particularly promising new fields of research, DTU ensures a high international
level within both the technical and natural sciences. It is DTU’s continuing goal
to be among the 10 best technical universities in Europe. Several independent
international rankings place DTU in this league.
3
BIOPEOPlE STAnDS FOR UnIQUE PARTnERSHIPS
Future developments in biomedical science, technology and innovation must include the
changing paradigm of our health system, where the focus is shifting to prevention, surveillance
and control. Effective development of new medicines, biotech, and med-tech products in this
challenging new arena requires mutually beneficial interaction, networking and public-private
partnerships. Competency-based relationships, mutual trust, confidence, and cooperation are
important and must grow in both the public and private sectors as well as across all biomedical
and technological disciplines.
Biopeople brings Danish stakeholders together in a unique collaboration for life sciences,
biomedical and med-tech innovations. As true triple-helix organisation, Biopeople includes
universities, research organisations, and hospitals, the Danish Medicines Agency, industry
associations as well as pharma, biotech and med-tech companies.
Biopeople is part of the new, permanent Danish infrastructure for innovation. Biopeople is
co-funded by the Danish Agency for Science, Technology and Innovation and the Danish Council
for Technology and Innovation. The partners of Biopeople comprises the vast majority public
research related to medicine, MedTech and biotech in Denmark.
Biopeople holds the secretarial support to the strategic university-industry partnership in
biomedical field, the Danish Pharma Consortium, chaired by Sven Frokjaer, Dean of The Faculty
of Pharmaceutical Sciences, University of Copenhagen.
Daan Crommelin, Scientific Director,
Dutch Top Institute Pharma:
Combining the knowledge present in science and industry is essential to the progress of future
biosciences and innovation. Successful past initiatives and future opportunities clearly show that
TI Pharma and Biopeople can join forces to the benefit of Denmark and the Netherlands, and to
the benefit of the international community of stakeholders with interest in innovation, in promoting
health care and in combating diseases.
4
Dutch Top Institute Pharma:
Combining the knowledge present in science and industry is essential to the progress of future
biosciences and innovation. Successful past initiatives and future opportunities clearly show that
TI Pharma and Biopeople can join forces to the benefit of Denmark and the Netherlands, and to
the benefit of the international community of stakeholders with interest in innovation, in promoting
5
SCIEnCE DATIng
Biopeople has pioneered a number of matchmaking event formats to promote cross-
disciplinary, public-private partnering and innovation within the biomedical and medical
device research and development communities. One of these event formats is Science
Dating
At Science Dating events people book short one on one meetings to reveal mutual research
interests. We have hosted several science dating events that each focused on a different
area within biomedical research. Through these events, hundreds of researchers have met to
brainstorm R&D collaborations across sectors and disciplines. These events also engage other
networks and scientific societies, attracting academia and industry from across the whole of
Denmark and internationally.
Goals and Benefits:
• Promote basic networking among peers, particularly across sectors and disciplines;
R&D community building
• Explore opportunities for novel public–private collaboration in medical device and
biomedical sciences; innovation brainstorming
• Advance research capacities through participation in the Industrial Ph.D. Programme;
cross-sector bridge-building plus R&D funding
6
Thomas Bjørnholm, Professor,
Nano-Science Center, Faculty of Natural Sciences, University of Copenhagen:
Science Dating events provide both the disciplinary breadth and the scientific intimacy needed for scientists and business people
to inspire one another towards innovation, and then get down to the nuts and bolts of setting up new R&D projects.
Jens Peter Vittrup, Special Advisor,
Danish Agency for Science, Technology and Innovation:
Between 2005 and 2007, we credit Science Dating Events with delivering
over 20 Industrial PhD studentships in the biomedical sciences.
7
EDUCATIO
n
A
n
D TRAI
n
I
ng
I
n
ITIATIVES
Biopeople facilitates translational research and collaboration across traditional barriers of
discipline and sector within biotech, med-tech and pharma. Wherever disciplines, regions,
nations, or sectors stand divided, our initiatives serve to strengthen public private cooperation
and relevant knowledge sharing among all stakeholders involved.
Specifically, the Biopeople network works to improve research training by:


Facilitating educational cooperation at tr
ansnational level


Facilitating intensive courses and workshops for industry resear
chers


Providing a better framework for mobility


Science Dating Events


Improving conditions for public-private collaborative resear
ch


Generally strengthening knowledge sharing across universities and industry


Ensuring that scientists gain experience from both academic and industrial research
As
Denmark’s national health care, life sciences and med-tech network, Biopeople positions
Denmark internationally through the visibility of its world class research. This acts to attract top
researchers and enhance the mobility of students. It also serves to harmonize developments
with the Bologna Process.
Selected initiatives:


Intensive courses in bioinformatics and systems biology


Medicines Research Academy


Danish Pharma Consortium


IMI Programme education and training


SHARE - Synergy Between Human and Animal Resear
ch
When you are looking for bioanalysis
Market-leaders in bioanalytical support for drug development studies, York Bioanalytical Solutions (YBS) and Capio
Diagnostik Denmark, have combined to form Unilabs Drug Development Services Group.
As a leading supplier of bioanalytical and logistics services to the global pharmaceutical and biotech industry,
Unilabs Drug Development Services offers a comprehensive list of analytical techniques: LC-MS/MS, ELISA, Gyros, MSD,
RIA and Molecular Biology to support bioanalytical method development and validation, as well as biomarkers and
safety analyses in drug development studies.
For further information on the wide range of services offered, please contact:
Unilabs, Denmark, Yvonne Lech, Tel: +45 3374 3091, yvonne.lech@unilabs.com
UNILABS IS EUROPE’S LEADING DIAGNOSTIC SERVICES COMPANY WITH MORE THAN 3000 EMPLOYEES IN DENMARK, FINLAND, FRANCE, ITALY, NORWAY, PORTUGAL, RUSSIA, SPAIN, SWEDEN,
SWITZERLAND, AND THE UNITED KINGDOM. www.unilabs.com
Novo Seeds administers a pre-seed program on behalf of the Novo
Nordisk Foundation. This unique program provides financial,
managerial and strategic support to Scandinavian projects with
commercial potential. The funding is given as grants, under the
same terms as other grants offered by the Novo Nordisk
Foundation, with no claims for equity or payback.
The pre-seed program offers an exceptional opportunity for
The pre-seed program offers an exceptional opportunity for
entrepreneurs and scientists with biotech projects to mature and
validate their scientific and business concept. We are actively
involved in helping pre-seed projects to develop into new biotech
endeavours, which hopefully enter the Novo Seeds portfolio.
Pre-seed grant
Seed investment
Novo Seeds are focusing on companies with outstanding potential
that typically are at a stage too early to attract financing from
Novo’s existing venture activities or other international investors.
The Novo seed program operates on commercial terms, whereby
investments in projects and companies are made in exchange for
ownership or other rights to the companies and/or projects.
Novo Seeds is a very active investor and we ensure the full benefit
Novo Seeds is a very active investor and we ensure the full benefit
for the portfolio companies of the broad network and capabilities
of the Novo organisation, and we assist with strategy, operational
issues and other corporate development.
We are inspired by the entrepreneurial
spirit and encourage everyone with an
idea for a biotech project to contact
us.
Sowing the seeds of tomorrows biotech successes
Novo Seeds
www.novonordiskfonden.dk
www.novo.dk
8
Discovery support
·
Literature search and screening
·
Identification of metabolites
·
Tox profiles of metabolites
Preclinical support
·
Design of optimal nonclinical package
·
Project management, CRO contact and monitoring
·
Ecotox testing
·
Tox assessment of impurities
Regulatory support
·
Nonclinical eCTD modules and SEND formats
·
Dossiers, investigator’s brochure (IB), investigational medicinal product
dossier (IMPD) and material safety data sheets (MSDS)
Discovery – Preclinical – Regulatory Support
DHI provides services within Life Science covering consumer
products such as drugs, medical devices and chemicals. DHI is your
professional partner in both discovery and preclinical development.
DHI, Human Health and Safety • Agern Allé 5 • 2970 Hørsholm • Denmark • Phone: +45 4516 9200
www.dhigroup.com/lifescience
∙ 200 companies, 2,500 FTE, EUR 1 billion R & D per year

∙ Strength: health, agriculture, food, environment, industry

∙ Broad range from small start-ups to multinational R & D divisions

∙ Strong R & D base of universities and PPPs.
Life sciences in the Netherlands
- your chance for a prosperous cooperation.
Want to know more?

Visit the website of the Life Science & Health Innovationprogramme
www.lifesciences.nl
or the branch organisations:
www.biofarmind.nl
www.niaba.nl
9
BIOPEOP
l
E –
THE
D
A
n
ISH
P
HARMA
In
DUSTR
y
Interview with Ida Sofie Jensen, CEO of the Danish Association of the Pharmaceutical Industry, Lif.
Why are public-private dialogue and cooperation necessary
for the pharmaceutical industry and the health research in Denmark?
Cooperation and dialogue between the public and private research sectors in the healthcare area is vital for
the continued development of new and improved treatments for patients. Today the costs of developing new
medicinal products are enormous. Therefore in Denmark we have a very natural and fruitful division of labour
between the public and private research sectors in the healthcare area, where the government is responsible
for basic research, as well as education and training of graduates and researchers, while the industry is
responsible for transforming basic research results into new innovative medicines. And Denmark benefits
greatly from this public-private cooperation.
Exports of pharmaceuticals in 2009 were approx. DKK 42 billion. About 17,000 people are employed in the
pharmaceutical industry, and each of them contributes with value to the Danish society of well over DKK 1
million. In addition to this, research into new medicinal products represents Denmark’s largest private research
area. Overall, industrial pharmaceutical research spends more than DKK 9 billion annually on new medicinal
products - 28% of all privately funded research here in Denmark. All in all, we are privileged by the very large
and powerful pharmaceutical industry which measured per capita is among the largest in the world.
What is unique about the Danish pharmaceutical industry?
The most unique feature of the Danish pharmaceutical industry is probably that several of the largest Danish
pharmaceutical companies are owned by foundations, which prevents them from being acquired by or merged
into other companies. This means that we in Denmark have not - as in many other countries - gone through
a phase where our national pharmaceutical industry has been merged into or acquired by large foreign
companies. At the same time, this has created an invaluable contribution to Danish research, as several of
the foundations behind these pharmaceutical companies support research into public health with hundreds
of millions of dollars each year.
Indeed, we have the unique situation here in Denmark that almost one third of all health science research
undertaken at public research institutions is funded by private foundations and companies. But it is clear, that
public investments in health research are also very important.
The pharmaceutical industry, among other things, depends entirely on the training of candidates and researchers
at both the universities and hospitals, and the industry is also completely dependent upon our strong clinical
research infrastructure. The clinical trial offers the industry the opportunity to test and approve its new medicinal
products, while also providing medical staff with knowledge about the use of the new health technologies,
ranging from diagnosis, treatment to effective follow-up. It is therefore not the issue that the government
should make money on private business, or vice versa. The aim is rather to create, develop, and thus improve
the synergy that has created an opportunity for our world-class pharmaceutical industry in Denmark.
10
11
About Lif
The Danish Association of the Pharmaceutical Industry (Lif) promotes the interests of the pharmaceutical industry
both here in Denmark as well as internationally. Our main operational areas are research and development,
production, marketing, and legal protection of corporate products. Lif also represents the pharmaceutical
industry’s general commercial, political and societal interests, while offering comprehensive information to
its 39 members.
Lif’s mission is to work to ensure that the pharmaceutical industry has the best possible conditions to research,
develop, market, distribute and provide information on medicinal products so as to ensure that patients have
extensive, fast access to the best medical treatment.
Lif’s vision is that: -The value of pharmaceuticals for the Danish society should be visible and recognised in
patient-centric health service.
- The pharmaceutical industry should be regarded as a responsible partner that makes a valuable contribution
to the community.
What factors have particular significance for the industry in conjunction with biohealth innovation?
The pharmaceutical, biotech, and medical device industries are all links in the “food chain” that we can refer
to as healthcare innovation, a chain that leads to both better products and better treatments. While research
in the pharmaceutical industry is largely self-financing and has its own focus areas, the biotech sector lies in
a cross field between the public sector and the private industry.
Perhaps we could draw some inspiration from the Dutch “Top Institute” model, which is based on a better
understanding of the need for cooperation between the public sector and the industry, and the knowledge
that public investment generates growth in the private sector.
Both the Danish Council for Strategic Research and the Danish Council for Technology and Innovation have
initiated similar programmes in Denmark for the food and energy industries, programmes called Strategic
Platform for Innovation and Research (SPIR) initiatives.
We would be delighted to see an SPIR initiative for the pharmaceutical industry next year. And from the
perspective of the pharmaceutical industry, the creation of the national biohealth innovation network Biopeople
is a very positive step in the right direction.
12
TOP ClInICAl AnD TRAnSlATIOnAl R&D
Today’s health care innovations need the top quality clinical research available through public-
private collaboration. No single stakeholder can provide solutions alone! Denmark has a
historically favourable position in providing world-class clinical research via access to patient
populations and its research infrastructure that facilitates results and progress.
Biopeople fosters an internationally-oriented world-class science environment where clinical and
translational R&D is conducted both responsibly and ethically. Clinical research is an essential
element of developing innovative healthcare products for the marketplace.
Our Advisory Board for Clinical and Translational R&D facilitates national strategies via both
analyses and discussions. We also enable knowledge sharing through meetings and training &
educational activities, ensuring best use of research facilities. And Biopeople brings researchers
together in new constellations via matchmaking events and tools. Our cross-disciplinary
approach to matchmaking helps clinical research to leverage other scientific “silo” disciplines,
such as preclinical research, bioimaging, and bioinformatics technologies.
Christian Gluud, Consultant MD, Head of the Copenhagen Trial Unit, Rigshospitalet,
Chairman Danish Clinical Research Infrastructures Network (DCRIN) and the Danish Clinical Research Consortium (DCRC):
Collaborations are needed in all stages of clinical research. Biopeople plays an instrumental role in strengthening the Danish
clinical trial infrastructure system to the benefit of public and private research and product development.
Anders Dejgaard, Corporate Medical Officer,
Novo Nordisk A/S:
Industry acknowledges Biopeople as a national collaboration that foster innovation in life
sciences and promote and support optimal conditions for clinical research in Denmark.
13
BIOETHICS FORUM
Biopeople’s Bioethics Forum is a neutral platform at the national level that focuses on the
bioethical issues related to development and production in the pharmaceutical, biotech and
med-tech industries. Through applied bioethics we can facilitate dialogue, mutual understanding,
and solutions to these issues.
The purpose is to help ensure Denmark’s position as world leader concerning the bioethical
challenges associated with research, development and production within the health care, life
sciences and med-tech sector.
The target audiences are researchers and future researchers within the biohealth sector,
citizens, and politicians.
The Bioethics Forum facilitates public-private cooperation in relation to common bioethical
challenges, such as:
• Developing educational and training material for students and researchers
• Effective and reliable communications for ethically controversial issues
• Providing a forum for input to the ethics committee system, for example in relation to
clinical research
• Animal and other preclinical research
• Sharing knowledge about methods, experiences and practical advice for solving
bioethical challenges
• Strengthening corporate capacity to manage these
• Experience from across sectors
Lise Holst, Director Global Bioethics Management,
Novo Nordisk A/S:
Biopeople’s Bioethics Forum is a valuable platform where industry, universities and hospitals can
meet for exchange and discussion of bioethical issues associated with research and development
14
RESEARCH PROJECTS
An important function of the Biopeople is to facilitate R&D collaboration projects between
academia and industry. Biopeople’s secretariat proactively identifies potential project partners
and offers advice on project funding. As Biopeople is part of the national innovation infrastructure
of the Danish Ministry of Science, Technology and Innovation, our focus is to align new projects
to earmarked government and national council funds; however Biopeople also monitors
feasibility of available regional and European sources of funding.
Biopeople facilitates partnering through matchmaking activities as well as via direct contact
to its extensive network of scientific experts from different disciplines of science. For example,
Public-Private Collaborative Projects facilitated by Biopeople must involve at least two companies
and at least two research institutions and the project must develop new knowledge to promote
growth and innovation among the partners while also including value or knowledge that can
be transferred beyond the project partnership. In these projects, Biopeople’s role can range
from discovering relevant partners and brokering the partnership through to dissemination of
the project’s ultimate value to a wider audience.
Soeren Moeller, CSO,
Exiqon A/S
I fully recommend Biopeople’s flexible and non-bureaucratic approach to facilitate industry collaborations
with academic institutions. These projects provide excellent opportunities for companies to get direct
and state of the art know-how in new scientific disciplines such as bioinformatics, and facilitate clinical
collaborations to benefit translational research projects and product development.
Previous research projects brokered by Biopeople showcase that both bioinformatics and
systems biology approaches make industry life sciences R&D more efficient. Examples include
collaboration projects between institutions such as University of Aarhus, the Technical University
of Denmark, and University of Copenhagen together with companies such as Novo Nordisk,
Novozymes, Chr. Hansen, Topotarget, Astra Zeneca, Exiqon and Santaris Pharma.
CORPORATE MEMBERSHIP
As part of the Danish research infrastructure Biopeople help companies to get access to public
research and knowledge. Public-Private collaborations must excel while both knowledge sharing
and development must grow to enhance innovation and research-based growth in the health
care, med-tech and life science sectors.
Biopeople continually develops new strategic approaches to align both Danish infrastructures
and Danish knowledge exchange to international and world-wide leading standards. We will
continue to pursue the approaches currently in use, such as promoting those translational
sciences that have value to business and fostering relevant new networks that enable innovation.
Biopeople encourages national and international biotech, pharma and med-tech companies
to become active members of our national organisation.
Your commitment to become a member is simply to designate one or more employees as
a “Biopeople Ambassador”, and to commit to participate in at least one of our many events.
Your Biopeople Ambassador will be our mutual two-way contact between your company and
Biopeople.
We also have an advanced form of membership offering free access to specialised training
courses and job advertising services.
Please contact the secretariat or visit www.biopeople.dk or for more information about corporate
membership.
15
BIOInFORMATICS & SySTEMS BIOlOgy
Computer technology is an integral part of modern research. This is especially true for the life
sciences where computer based analysis of biological data is involved in all phases of research,
from laboratory experiments to clinical trials. Today researchers rely on bioinformatics software
tools to handle large complex data sets derived from genome sequencing, DNA microarrays,
proteomics, high through-put screening and so on.
In today’s marketplace, the ability to extract new insights by integrating propriety data with
information in the rapidly growing public databases is becoming an important competitive
factor. Bioinformatics tools and expertise can generate accurate predictions that will guide
and focus your R&D, making it significantly more time and cost effective.
Happily, getting these cost and time savings in Denmark does not require a huge investment in
personnel and infrastructure; Danish scientists have been among the pioneers in bioinformatics
and over the last 15 years, strong scientific environments with sufficient critical mass and
advanced computer infrastructure have emerged at several public science institutions in
Denmark. Recognizing the great value of these resources, more and more companies and public
research groups outsource the bioinformatics part of their research projects in collaboration
with the academic experts.
Your organization can also benefit from assistance with bioinformatics related issues. Corporate
members of Biopeople get help identifying the right research groups for your special needs
and we can facilitate your collaboration with such groups. Biopeople also organizes courses
and workshops to keep your organisation up-to-date with developments in bioinformatics and
systems biology. Biopeople includes an Advisory Board for bioinformatics and systems biology
for strategic coordination of activities.
If you feel your organization could be better prepared for the modern era of -omics technologies,
please contact Biopeople.
Nikolaj Blom, Senior Department Manager,
Novozymes A/S:
We are witnessing a “tsunami” of biological data that is forming the basis for the next leap in biobased innovations. In order to
transform this data into useful knowledge we need massive computational power and talented experts in bioinformatics and
systems biology. A concerted effort of academic and industrial partners is required and we therefore strongly support Biopeople.
B
IOPEOP
l
E
-
THE
D
A
n
ISH
M
ED
T
ECH
In
DUSTR
y
Interview with Jens Kristian Gøtrik, Director at Medicoindustrien
Why are public-private dialogue and public-private partnership necessary
to promote Life science innovation in Denmark?
Within the context of “Life Science”, the medical device industry enjoys faster growth than even the
pharmaceutical industry. It is the combination of researcher in academic environments together with
hospitals and industry that produces innovative products, and these are the three key players who in
constructive interactions enable the huge potential that can only be exploited optimally through an
open approach to knowledge and knowledge sharing.
We must create a network of researchers - and use it both creatively and constructively - with participants
from all three of these environments. Why? To cope with the up and coming strong international growth
drivers in this area: Brazil, Russia, India and China (popularly called BRIC countries). Our large companies
are attractive in themselves acting as magnets for both human skills and capital, but our small and
medium enterprises (SMEs) – and particularly the small - have a great need for and great potential
benefit from a national network, that can also operate on an international level. And Denmark will
benefit from an interdisciplinary forum that serves as a framework for interdisciplinary collaboration,
both in relation to preventing and fighting disease as well as in relation to GDP and economic growth.
What is unique about the Danish medical device industry?
Danish medical companies are good at commercializing their innovations. Coloplast, BK Medical,
Radiometer, and the hearing aid industry, such as GN and Oticon, are good examples of companies
that have combined knowledge from the medical and engineering communities. In Denmark we have
a plethora of smaller companies each possessing knowledge that can be valuable in itself, but through
interaction with other areas of knowledge can create entirely new solutions. SMEs account for 80% of
all companies within the Life Science sector. Greater levels of knowledge sharing among them would
contribute a value input of unknown dimensions to the whole sector. The researchers’ innovations
in the network must not overlap, but create synergies. To succeed in this increased value through
synergies, each of us must find his or her own role in relation to others and, for this transparency in
knowledge sharing is a prerequisite.
16
About Medicoindustrien
Medicoindustrien is the industry association for companies in Denmark that develop, manufacture, sell
or otherwise have an interest in medical devices. The association aims to promote the professional
and political interests of its members, currently numbering 110 companies.
In Denmark Medicoindustrien’s consults with the authorities on issues and matters that concern the
medical devices industry. Medicoindustrien actively participates on councils and committees that have
influence on the business environment for the industry.
At an international level, Medicoindustrien plays an active role in the common European trade
organization EUCOMED and cooperates with European and American sister organizations.
What needs and desires does Medicoindustrien have for the Biopeople innovation network?
To contribute to a productive and positive development, both universities and hospitals should have
laboratories for innovation. This will require that research groups and health practitioners know each
other and each other’s work, tasks and competencies. 30 years ago, we could show the world that
we were world leaders in these areas of cooperation, but the medical community has taken quantum
leap since then. To maintain our strong position and to continue to be among the leading explorer and
pioneering communities, we must demonstrate that we are technological frontrunners in Life Science
in a broader sense. Compare, for example, the healthcare sector with the green-tech field. To succeed
in green-tech, we must be able to show a district heating plant based on green energy. To succeed
in home healthcare, we must be able to show a system with remote technical solutions. Again from
green area in general, we need to show utensils, tubes, needles, and plasters that function without
use of ptalater and unhealthy softening agents. We must stimulate the industry to be able to present
such solutions.
What key elements do you see for the medical device industry in Life science innovation?
We must have easy access to the expertise that already exists. What’s going on in universities and
hospitals, for example, in nanoscience? In stem cells? We must provide opportunities for a greater
overview. The big companies have scouts out seeking new knowledge, but SMEs cannot begin to consider
this luxury on their own. Networking among the pharmaceutical industry, the medical device industry,
the biotechnology industry, hospitals, and universities is essential. The establishment of Biopeople will
provide better access for each of us to other areas of Life Science, to the opportunities in other areas
of knowledge, and last but not least, create a national perspective.
17
18
DAnISH MED-TECH
Biopeople aims to strengthen the medical device industry in Denmark by facilitating collaboration
and meetings across both sectors and disciplines, thereby ensuring better innovation.
Since the Biopeople network contains not only the pharmaceutical industry but also the
biotechnology and medical device industries, we are able to breakdown industry specific
barriers and to bring people with very different skills together. At the same time, the transnational
aspect of Biopeople allows better contact between researchers and businesses across the
distinct regions within Denmark.
The cross disciplinary structure of Biopeople combined with the national outreach makes it
feasible for the network to:
• Establish cooperation between regional clusters within the medical devices sector
• Identify and increase the visibility of the many SMEs; enables “critical mass” for the
network
• Increase cooperation between the very different technology fields within the industry
• Increase cooperation and knowledge sharing between industry-based research and
the healthcare sector
• Share knowledge concerning the clinical testing of products
• Share knowledge concerning health care requirements and decision-making relative
to procurement of new technology
Selected regional med-tech and medical-device clusters:
• BioMed Community (www.biomedcom.dk)
• MedTech Innovation Center (www.mtic.dk)
Danish med-tech facts:
• There are approx. 220 companies dedicated to medical device work in Denmark
• Total turn over of DKK 40 billion
• Employs approx. 20,000 in Denmark and 20,000 abroad
• Establishes 8-9 new companies in Denmark per year
• High innovation rate - products are on average only in the market for 1.5 years before
there is a new and better solution
Source: Med-tech sector in Denmark, Growth Fund 2009
A groundbreaking research project is currently being undertaken by Associate
Professor Trine R. Thomsen, Professor Per Halkjær Nielsen and other parties.
The goal of the project is to implement new, improved molecular methods for
the diagnosis of bacterial infections. The work will ensure a more reliable and
faster diagnosis of infections and thereby enable more efficient treatment and
consequently shorter hospitalization of patients.
The Department of Biotechnology, Chemistry and Environmental Engineering
provides the research framework for the engineering study programmes in
Medical Biotechnology, Biotechnology, Chemical Engineering and Environmen-
tal Engineering as well as the Chemical and Biological Sciences programmes.
The Department is the main player, both for the joint Bachelor’s programmes
and for the different graduate specializations within the field.
The Department employs approx. 175 persons, and approx. 75 Master’s
students and 15 Ph.D. students graduate every year.
The Department is located at Aalborg University at the Aalborg, Esbjerg and
Copenhagen campuses.
We are always interested in developing further co-operation.
Find us at www.bio.aau.dk.
For more
information
visit us at
bio.aau.dk
Introducing a revolutionary shift in
the medical microbiology paradigm
LAB Research A/S
Hestehavevej 36A, Ejby
DK-4623 Ll. Skensved
Denmark
www.LABresearch.dk
info@labresearch.dk
Comprehensive non-clinical
services based on scienti￿ c reliability
• Biological testing
• Bioavailability and immunology
• Toxicology and pharmacology testing
• Biocompatibility testing of medical devices
With 30 years of experience with drug and device development and
three sites distributed across North America and Europe, LAB Research
o￿ ers a broad range of services and support laboratories.
Workshops in Berlin, Einsteinpalais 2010
February | July | September
From technology to start up your business
Hightech-Marketing
Investor Presentation
• From technology transfer to
accelerating your business
- our expertise makes the di￿ erence
• Marketing, sales, ￿ nance
• Service packages for start ups
Book at www.abtconsult.com or +49 30 30366 5334
www.abtconsult.com
ABT-Consulting
Levnedsmiddelcentret (LMC)
koordinerer den offentlige fødevarerelaterede forskning i Danmark
i samarbejde med Landbrug og Fødevarer samt DI Fødevarer.
Yderligere information: www.lmc.dk
19
Envisioning future solutions.
Engaging research.
Cooperation and cutting edge research within
proteomics, genomics, lipidomics, bioimaging,
clinical research and animal models.
UNIVERSITY OF SOUTHERN DENMARK
The Faculty of Health Sciences and
The Faculty of Science
SDU.DK
Frontline research &
business interphase
Contact: Squareone@sdu.dk
20
Ole Maaløes Vej 3
DK - 2200 Copenhagen N
www.cobis.dk
Your professional
biotech environment
biotech environment
biotech environment
COBIS is now open for large and small projects and companies
ŝŚŝŶ>ŝĨĞ^ĐŝĞŶĐĞtĞŽīĞďĂŶĚŶĞĨĂĐŝůŝĞĚĞŝŐŶĞĚŽ
support the growth of your company.
Give us a call today and learn more: +45 70 70 29 80
or email us: info@cobis.dk.
21
B
IOPEOP
l
E
-
THE
D
A
n
ISH
B
IOTECH
In
DUSTR
y
Interview with Søren Carlsen, Chairman of Dansk Biotek and managing partner of Novo A/S
Why are public-private dialogue and public-private partnership necessary to promote Life science
innovation in Denmark?
Innovation in health research happens at many levels, both in terms of the number of stakeholders in
this group and also the interdisciplinary skills each of them brings to the table. Denmark has a good
tradition for basic research in biotechnology and medicine, and is in several areas world-leading in
medical research; for example, Novo Nordisk within diabetes, Leo for skin diseases, and Lundbeck
within pharmaceuticals related to the central nervous system.
Denmark already has a strong research basis within both the public and private sectors, and the
results are commercially significant; Novo Nordisk alone is responsible for 40% of worldwide sales of
insulin related medicine, and Novozymes is the world-leader in terms ofi ndustrial biotechnology. Our
universities and hospitals deliver a good framework for clinical trials, showing great understanding of
the importance of cooperation with industry.
Nevertheless, we must admit that we are lagging 10-20 years behind the U.S., where there is both
a greater focus on applied research and traditionally a closer relationship between universities and
industry. Researchers often serve as corporate directors and there is not the same reluctance to
engage in the commercial world that we often see from academia in Denmark. In 2000 (see above)we
created technology transfer offices at universities with the aim of intensifying the knowledge transfer
from universities to industry, but to date without the impact we had hoped. So we could still benefit
from adopting other aspects of the American tradition to our Danish conditions. In this respect, I see
the Biopeople Life science innovation network as a worthwhile addition to the landscape.
22
What is unique about Danish biotech companies?
Within biotechnology, we have the large plastic technical(??? See above) companies, which have a
positive and high profile position, attracting both investors and competence. But we also have an
interesting plethora of approximately 40 to 50 small businesses that have taken off in new directions
and are engaged in exciting projects and products. These new companies often find it difficult to attract
resources and people before they have proven their commercial viability, needing help and frameworks
to provide venture capital or to enter into partnerships with the pharmaceutical industry. But Denmark
has many well-founded clinical research studies, particularly in relation to our size. In Europe we are
No. 3 overall - after Germany and England - and with respect to population we are No. 1. We have
a fertile foundation for biotech research, a foundation that can be further improved by increasing
interdisciplinary relationships and - politically - creating better framework conditions for enterprises.
Why should investors be interested in Danish biotech companies?
I would argue that Danish research is characterized by a good entrepreneurial spirit. We have a broad
experience base plus a good recruiting base to attract developers and to create interaction between
the private sector and the public research community. In my capacity as Managing Partner of Novo A
/ S and through my influence of our venture capital activities, I can say that we have no geographical
preferences in relation to EU/USA. . We are keen for more international investors and are investing in
syndicates, where we reciprocally point to international investors and investment companies.
What other priorities do you see for Dansk Biotek and Life science innovation?
We must examine the framework conditions for Danish biotech research and send a message to the
politicians for greater funding of Proof-of-Concept investments as well as financial help for small and
medium enterprises (SMEs). It is important and worthwhile for Denmark to promote the knowledge
society and a huge challenge to keep up with countries like China and India. We cannot rely alone on
being at the forefront of the exciting innovative research work, leaving the industrial production to
low wage countries. Their research environments are growing very fast and they wish to be able to
compete on the knowledge creation front, too. We have as you know, the world’s highest tax burden,
but even with particularly attractive tax schemes for foreign scientists, we cannot expect to attract
and retain foreign researchers, let alone hold onto the best Danes. We have a good start and a good
position but these are not unique. Our innovation conditions must not only be maintained but must
be improved. I think the idea and structure of Biopeople is an approach that will serve the purpose of
strengthening, supporting and expanding biomedical and biotechnology research, as well as education
and training of academics, hospital staff, and industry.
23
About Dansk Biotek
Dansk Biotek works to improve and create the best conditions for biotechnological research and
production in Denmark, and to further the common interests of members, nationally and internationally.
Denmark must be a world-leader in biotechnology to attract, increase, and preserve the biotech industry’s
research and development, and production, as well as the associated export and employment the
industry brings.
24
BIOPEOPlE COOPERATIOn
WITH REgIOnAl ORgAnISATIOnS AnD nETWORKS
As the national innovation network for the biotech, pharmaceutical and medical device industry,
Biopeople must facilitate collaboration and knowledge sharing across sectors and regions. One
prerequisite for this is that existing stakeholders in areas relating to health care, life sciences
and med-tech are invited to participate as active players. Biopeople’s partners represent Danish
public research, whiles its members come from the private research milieu.
Both partners and members belong to the community-based network that serves to nurture
regional interests. Biopeople also invites all relevant network organizations to cooperate across
regional interests so that the national forces within the health care, life sciences and med-tech
sectors promote the best.
The ambition for Biopeople is to help coordinate efforts with and among existing networks
by including them as associates in the network. It is crucial to ensure optimum utilization of
resources wherever possible, to choose cooperation instead of repetition in overlapping areas
and initiatives.
The close cooperation with enterprises, research institutions and regional networks offers a world
class platform for creating new collaborations with foreign companies and researchers as well.
Danish networks / organisations within Life Sciences:
• Invest in Denmark (www.investindk.com)
• Copenhagen Capacity (www.copcap.com, www.mediconvalley.com)
• Medicon Valley Alliance (www.mva.org)
• BioMed Community (www.biomedcom.dk)
• MedTech innovation Center (www.mtic.dk)
25
BIOTECH PARTnERIng MISSIOnS
Biopeople has pioneered a number of matchmaking event formats to promote cross-disciplinary,
public-private partnering and innovation within the biomedical and medical device research and
development (R&D) communities. One of these event formats is our Biotech Partnering Missions.
At Biotech Partnering missions SME’s and academics from bioclusters abroad are matched
with relevant Danish companies and academics to discuss research and business opportunies.
Through these events, hundreds of SMEs and researchers have agreed to meet to brainstorm
collaborations, to form strategic alliances and to do business across both sectors and disciplines.
Goals and Benefits:
• Promote international networking among European bioclusters, particularly across
disciplines; international R&D community building
• Explore opportunities for novel collaboration in biomedical and medical device sciences
and business; innovation brainstorming
• Advance Denmark as a premier bioregion on the European scene; international business
promotion and biocluster bridge-building
Alistair Hurst, Managing Director,
Biotech IgG:
Participating in the 2009 Dutch-Danish Biotech Partnering Mission has brought Biotech-IgG a new business
partner, enabling us to both broaden our product line and increase our customer base throughout Scandinavia.
26
OnlInE DATABASES
Matchmaking also occurs online, where people seek equipment or expertise by keyword.
Biopeople’s databases enable partnering across sectors and disciplines for important sets of
enabling technologies, e.g.: Animal Models and Bioimaging. We also have an online catalogue
of rare, expensive or unique equipment in our Technologies and Facilities database.
Our online databases have emerged from our matchmaking events, where participants have
provided brief descriptions of the equipment and expertise they are keen to share in research
and development (R&D) or business collaborations. Through these routinely updated databases,
both small to medium-size enterprises (SMEs) and academic researchers have agreed to
explore opportunities that will reduce their R&D bottlenecks and enable pilot projects, as well
as to form alliances.
Goals and Benefits:
• Stimulate durable cooperation between SMEs and public research facilities; increased
scope for international research and business collaboration
• Promote competences, expertise and facilities available; SMEs know which facilities
and what expertise are available and where
• Give SMEs a contact point for both information and support in accessing relevant
facilities; international business promotion and biocluster bridge-building
Axel Kornerup Hansen, Professor,
Faculty of Life Sciences, University of Copenhagen:
The existence of an online database for animal models is a boon to public-
private collaboration within preclinical research and development.
27
PREClInICAl AnD TRAnSlATIOnAl R&D
As Denmark’s biomedical and med-tech innovation network, Biopeople’s partners hold a
wealth of resources and competencies in preclinical disciplines of importance to medicines
and medical device R&D and product development.
Future developments in biomedical science, technology and innovation must include the
changing paradigm of our health system, where the focus is shifting to prevention, surveillance
and control. Effective development of new medicines, biotech, and med-tech products in this
challenging new arena requires mutually beneficial interaction, networking and public-private
partnerships. Knowledge and facilities must be shared to stimulate research and networking.
This sharing, in return, benefits business, patients, and society as a whole.
Biopeople has a long history of prioritising the Danish competency strongholds of experimental
animal models and laboratory facilities, safety sciences, biobanks and registries, and bioethics,
as well as leveraging cross-disciplinary research from “bench to bedside” and back again. We
will continue to focus on these and other priority area to maintain and grow Denmark’s leading
international position in life sciences and innovation for our partners and member companies.
Biopeople supports SHARE initiative at University of Copenhagen (Synergy in Human and Animal
Research initiative, www.share.life.ku.dk.
Lars H. Pedersen, Ph.D., Director R&D and Operations,
Bioneer A/S:
We develop new product, process and service opportunities by cross-linking ideas from the world
of science with needs of the market. In this matter we benefit a lot from the partnership.
Thomas Mandrup-Poulsen, Professor, Director, Center for Medical Research Methodology,
University of Copenhagen, and Dept. of Translational Diabetology, Hagedorn Research Institute.
The aspiration of Biopeople is to walk the talk to promote translational aspects of modern medicines R&D.
University of Copenhagen
Universitetsparken 1,1
st
DK-2100 Copenhagen
Denmark
Phone: +45 35 32 62 40
Email: info@biopeople.dk
www.biopeople.dk
• www.jsdanmark.dk
• 500610 • Trykt på officielt godkendt miljøvenligt papir •
Trykfarverne er baseret på vegetabilske olier • Koncept: JS Media Tools • Copyrights Biopeople
Biotech Medtech PharMa